Is ArriVent BioPharma, Inc. (AVBP) a Buy, Sell, or Hold?
ArriVent BioPharma, Inc.
NASDAQ:AVBP
$32.99 USD
$0.45 (1.38%)
- Volume
- 43.93K
- Average Volume
- 548.21K
- Market Capitalization
- $1.54B
- P/E Ratio
- -9.35
- Dividend Yield
- 0.00%
- Price Target
- $45.00
- Year High
- $35.83
- Year Low
- $16.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.95
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Zhengbin Yao |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AVBP |
| CUSIP | 04272N102 |
| CIK | 0001868279 |
| Web | https://arrivent.com |
| Phone | 628-277-4836 |
| Currency | USD |
| Employees | 77 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 13.95 |
| Quick Ratio | 13.95 |
| Cash Ratio | 2.48 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -2.98 |
| Price / Cash Flow | -11.43 |
| Price / Book | 4.59 |
Price Target and Rating
| Average Stock Price Forecast | $45.00 |
| High Stock Price Forecast | $45.00 |
| Low Stock Price Forecast | $45.00 |
| Forecast Upside/Downside | -26.69% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 7 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.32 |
| Trailing P/E Ratio | -9.35 |
| PEG Ratio | -9.12 |
| P/E Growth | -9.12 |
| Net Income | $-166.31M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -48.98% |
| Return on Assets | -41.58% |
Financials Score
| AltmanZ Score | 34.63 |
| Piotroski Score | 1.00 |
| Working Capital | 323.7M |
| Total Assets | 349.3M |
| Ebit | -145.24M |
| Market Cap | 1.55B |
| Total Liabilities | 25.32M |
Poll Results
About ArriVent BioPharma, Inc. (NASDAQ:AVBP) Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, ... an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case
2026-05-16 09:32:39
Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulation rather than operational issues, enrollment challenges, or trial redesign. ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term funding risk while supporting late-stage development and commercialization efforts. Shanghai Allist continues to demonstrate strong commercial momentum in China, while ARR-002 adds a new potential growth driver.
ArriVent BioPharma Reports First Quarter 2026 Financial Results
2026-05-11 16:01:00
NEWTOWN SQUARE, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent Company progress.
2026-05-07 08:00:00
NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts
2026-04-24 02:12:48
Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
2026-04-15 13:01:16
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Frequently Asked Questions
-
What is the current ArriVent BioPharma, Inc. (AVBP) stock price?
-
ArriVent BioPharma, Inc.(NASDAQ:AVBP) stock price is $32.99 in the last trading session. During the trading session, AVBP stock reached the peak price of $35.83 while $16.1 was the lowest point it dropped to. The percentage change in AVBP stock occurred in the recent session was 1.38% while the dollar amount for the price change in AVBP stock was $0.45.
-
AVBP's industry and sector of operation?
-
The NASDAQ listed AVBP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AVBP?
-
James Paul Kastenmayer | General Counsel & Secretary
Stuart Lutzker | Co-Founder, President of Research & Development and Director
Zhengbin Yao | Co-Founder, Chairman, President & Chief Executive Officer
Brent S. Rice | Chief Commercial Officer
Winston Kung | Chief Financial Officer & Treasurer -
How many employees does AVBP have?
-
Number of AVBP employees currently stands at 77. AVBP operates from 18 Campus Boulevard Suite 100, Newtown Square, PA 19073, US.
-
Link for AVBP official website?
-
Official Website of AVBP is: https://arrivent.com
-
How do I contact AVBP?
-
AVBP could be contacted at phone #628-277-4836 and can also be accessed through its website. AVBP operates from 18 Campus Boulevard Suite 100, Newtown Square, PA 19073, US.
-
How many shares of AVBP are traded daily?
-
The average number of AVBP shares traded daily for last 3 months was 548.21K.
-
What is the market cap of AVBP currently?
-
The market value of AVBP currently stands at $1.54B with its latest stock price at $32.99